Does CABAZITAXEL Cause Malignant neoplasm progression? 172 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 172 reports of Malignant neoplasm progression have been filed in association with CABAZITAXEL (Jevtana). This represents 6.7% of all adverse event reports for CABAZITAXEL.
172
Reports of Malignant neoplasm progression with CABAZITAXEL
6.7%
of all CABAZITAXEL reports
18
Deaths
23
Hospitalizations
How Dangerous Is Malignant neoplasm progression From CABAZITAXEL?
Of the 172 reports, 18 (10.5%) resulted in death, 23 (13.4%) required hospitalization, and 6 (3.5%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CABAZITAXEL. However, 172 reports have been filed with the FAERS database.
What Other Side Effects Does CABAZITAXEL Cause?
Febrile neutropenia (197)
Fatigue (160)
Prostatic specific antigen increased (148)
Pyrexia (145)
Disease progression (143)
Diarrhoea (142)
Anaemia (127)
Neutropenia (126)
Drug ineffective (125)
Dyspnoea (113)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which CABAZITAXEL Alternatives Have Lower Malignant neoplasm progression Risk?
CABAZITAXEL vs CABERGOLINE
CABAZITAXEL vs CABOTEGRAVIR
CABAZITAXEL vs CABOTEGRAVIR\RILPIVIRINE
CABAZITAXEL vs CABOZANTINIB
CABAZITAXEL vs CABOZANTINIB S-MALATE